Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900665 · ClinicalTrials.gov registry record · Phase 3
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,129
- Enrollment target
NCT01900665: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT01900665 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 2,129 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (176% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01900665, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,129 participants
- Enrollment target
Study Summary
To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
Primary Outcome
The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS that was used as the primary efficacy measure consists of 14 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze completion measures. The ADAS-Cog14 scale ranges f
Interventions
- DRUG Placebo
- DRUG Solanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,129 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Why NCT01900665 stopped before completion
NCT01900665 is an interventional study that assigns participants to a tested intervention. Its 2,129 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (176% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01900665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01900665 about?
NCT01900665 is a clinical study titled "Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo". To test the idea that solanezumab will slow the cognitive decline of Alzheimer's Disease (AD) as compared with placebo in participants with mild AD.
What is the current status of trial NCT01900665?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,129 participants. The study started on 2013-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01900665?
The interventions under investigation include: Placebo (DRUG), Solanezumab (DRUG).
Who is sponsoring clinical trial NCT01900665?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01900665's enrollment target sits among peer trials
2,129 98th of 2000 higher than 1,903 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia